Diabetes drug trial offers hope for teens with fatty livers
NCT ID NCT06355310
Summary
This study is testing if a medication called empagliflozin, currently used for diabetes, can safely reduce fat in the liver of obese teenagers with non-alcoholic fatty liver disease (NAFLD). Forty adolescents will take the drug or a placebo for 26 weeks while also receiving lifestyle counseling. The main goal is to see if the drug lowers liver fat, measured by MRI scans, and to check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ann & Robert H Lurie Children's Hospital of Chicago
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.